在儿童1型糖尿病护理中,对技术介导的同行支持干预措施进行系统审查
Reena Titoria1, Andrea Fung2, Tricia S Tang3
1Provincial Health Services Authority, Vancouver, British Columbia, Canada.
概括
技术介导的同行支持显示了改善儿科1型糖尿病护理的潜力. 虽然并没有持续改善心理社会结果,但一些研究指出降低了低血糖症,这需要进一步研究.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 数字健康数字健康
- 行为医学是一种行为医学.
背景情况:
- 在糖尿病管理中,越来越多地认识到同行支持.
- 对儿科1型糖尿病的技术介导的同行支持研究不足.
- 干预措施旨在支持儿童,护理人员和医疗保健提供者.
研究的目的:
- 描述1型糖尿病儿童的技术介导的同行支持干预措施.
- 分析它们对临床,行为和心理社会结果的影响.
- 确定研究当前的趋势和差距.
主要方法:
- 在CINAHL,Embase和MEDLINE的系统文献搜索 (2007年1月至2022年6月).
- 包括随机和非随机试验,重点关注儿童糖尿病的同行支持.
- 使用Cochrane偏差风险工具进行质量评估.
主要成果:
- 包括12项研究,使用短信,视频,网络门户和社交媒体.
- 大多数干预措施都针对儿童,但没有发现显著的心理社会改善.
- 对HbA1c的结果各不相同;一些研究报告说,降低了低血糖的发生率.
结论:
- 技术介导的同行支持可能会为糖尿病护理和治疗结果带来好处.
- 需要进一步进行高质量的研究,以解决多样化的人口和干预可持续性的问题.
- 精心设计的研究对于优化儿童糖尿病技术驱动的同行支持至关重要.
相关概念视频
Self-Help Support Groups
59
Self-help support groups are voluntary, community-based organizations that provide a platform for individuals with shared concerns to exchange support, insights, and practical strategies for coping with life challenges. Typically led by group members or paraprofessionals, these groups form a cornerstone of mental health care, especially in reaching populations that are underserved by traditional healthcare systems.
Accessibility and Cost-Effectiveness
One of the primary strengths of self-help...
Accessibility and Cost-Effectiveness
One of the primary strengths of self-help...
59
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Insulin: Dosing Regimen and Adverse Effects
213
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
213


